NCT03594630
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
At risk: Primary completion moved 2 years later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 13 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028
- Eligibility criteria expanded, about 18 words
- Secondary endpoints: details revised at 1 of 7 entries
- Study Identification, Study Status, Oversight, Conditionsv14
- Study Identification, Study Status, Oversight, Conditionsv13
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Oct 31, 2024 to Mar 13, 2024
- Site details revised
- Notable Primary and study completion dates: Oct 31, 2024 to Oct 31, 2026
- Start date: Oct 31, 2023 to Oct 31, 2024
Show 7 earlier versionsHide 7 earlier versions
- Notable Start date: Oct 31, 2022 to Oct 31, 2023v9
- Notable Start date: Oct 31, 2020 to Oct 31, 2022v7
- Notable Start date: Oct 2019 to Oct 31, 2020
- Primary completion date: Oct 2024 to Oct 31, 2024
- Study completion date: Oct 2025 to Oct 31, 2024
- Notable Primary completion date: Jan 2020 to Oct 2024
- Start date: Jan 18, 2019 to Oct 2019
- Study completion date: Jan 2020 to Oct 2025
- Notable Primary and study completion dates: Jan 31, 2019 to Jan 2020
- Start date: Oct 18, 2018 to Jan 18, 2019
- Notable Start date: Aug 18, 2018 to Oct 18, 2018v3
- Minor Site contact updatedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants who have achieved clinical complete response undergo standard surgical resection.
Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
Drugs: Chemotherapy
Other: Patient Observation, Questionnaire Administration
Procedures: Resection of Rectum
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States